Shopping Cart
Remove All
Your shopping cart is currently empty
HPN-01 (IKK inhibitor XII) is a selective IKK inhibitor that inhibits IKK-α, IKK-β, and IKK-ε. HPN-01 reduces the severity of the disease, attenuates the immune imbalance, and prolongs the lifespan of mice in a model of autoimmune encephalomyelitis, and can be used to study immune disorders.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $147 | - | In Stock | |
| 5 mg | $247 | - | In Stock | |
| 10 mg | $396 | - | In Stock | |
| 25 mg | $787 | - | In Stock | |
| 50 mg | $1,180 | - | In Stock | |
| 100 mg | $1,780 | - | In Stock | |
| 200 mg | $2,430 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $272 | - | In Stock |
| Description | HPN-01 (IKK inhibitor XII) is a selective IKK inhibitor that inhibits IKK-α, IKK-β, and IKK-ε. HPN-01 reduces the severity of the disease, attenuates the immune imbalance, and prolongs the lifespan of mice in a model of autoimmune encephalomyelitis, and can be used to study immune disorders. |
| Targets&IC50 | IKKε:4.8(pIC50), IKKα:6.4(pIC50), IKKβ:7(pIC50), IKKα:6.4 (pIC50), IKKβ:7 (pIC50), IKKε:4.8 (pIC50) |
| In vitro | HPN-01 could inhibit the expression of SREBP-1 and SREBP-2 in human primary hepatocytes, and the IC50 values were 1.71 and 3.43, respectively. It is commonly used in the study of nonalcoholic fatty liver disease (NAFLD)[1]. |
| Synonyms | HPN01, HPN 01 |
| Molecular Weight | 401.87 |
| Formula | C19H16ClN3O3S |
| Cas No. | 928655-63-4 |
| Smiles | NC(=O)c1cc(cc(c1N)-c1ccc(cc1)S(N)(=O)=O)-c1ccc(Cl)cc1 |
| Relative Density. | 1.425 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (199.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.